Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils

Blood

Volumn 88, Issue 12, 1996, Pages 4684-4693

  Elsner, Jörn ^a   Höchstetter, Renate ^b   Spiekermann, Karsten ^b   Kapp, Alexander ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTAXIN; GLYCOSYLPHOSPHATIDYLINOSITOL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 3; LYMPHOCYTE SURFACE MARKER; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE;

ANTIGEN EXPRESSION; ARTICLE; BACTERIAL INFECTION; CROSS LINKING; EFFECTOR CELL; EOSINOPHIL; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; NEUTROPHIL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION;

EID: 0029912735     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.12.4684.bloodjournal88124684     Document Type: Article

References (49)

1. Smith JA: Neutrophils, host defense, and inflammation: A double-edged sword. J Leukoc Biol 56:672, 1994
2. Weller PF: The immunobiology of eosinophils. N Engl J Med 324:1110, 1991
3. Kapp A: The role of eosinophils in the pathogenesis of atopic dermatitis - Eosinophil granule proteins as markers of disease activity. Allergy 48:1, 1993
4. Ying S, Taborda-Barata L, Meng Q, Humbert M, Kay AB: The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: Relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 181:2153, 1995
5. Dhami D, Shutte JK: Mechanisms of epithelial damage: Are there parallels between bullous skin diseases and asthma? Clin Exp Allergy 24:1005, 1994
6. Aractingi S, Janin A, Zini JM, Gauthier MS, Chauvenet L, Tobelem G, Prin L, Chosidow O, Frances C: Specific mucosal erosions in hypereosinophilic syndrome: Evidence for eosinophil protein deposition. Arch Dermatol 132:535, 1996
7. Kita H, Gleich GJ: Chemokines active on eosinophils: Potential roles in allergic inflammation. J Exp Med 183:2421, 1996
8. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, Baggiolini M, Sykes BD: Structure-activity relationships of chemokines. J Leukoc Biol 57:703, 1995
9. Elsner J, Oppermann M, Czech W, Dobos G, Schöpf E, Norgauer J, Kapp A: C3a activates oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24:518, 1994
10. Elsner J, Oppermann M, Czech W, Kapp A: C3a activates the respiratory burst in human polymorphonuclear leukocytes via pertussis toxin sensitive G-proteins. Blood 83:324, 1994
11. Zeck-Kapp G, Kroegel C, Riede UN, Kapp A: Mechanism of human eosinophil activation by complement protein C5a and platelet-activating factor: Similar functional responses are accompanied by different morphologic alterations. Allergy 50:34, 1995
12. Elsner J, Opperman M, Kapp A: Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Eur J Immunol 26:1560, 1996
13. Kameyoshi Y, Dörschner A, Mallet AI, Christophers E, Schröder JM: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587, 1992
14. Alam R, Stafford S, Forythe P, Harrison R, Faubion D, Lett-Brown MA, Grant JA: RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 150:3442, 1993
15. Kapp A, Zeck-Kapp G, Czech W, Schöpf E: The chemokine RANTES is more than a chemoattractant: Characterization of its effect on human eosinophil oxidative metabolism and morphology in comparision with IL-5 and GM-CSF. J Invest Dermatol 102:906, 1994
16. Weber M, Uguccioni M, Ochsenberger B, Baggiolini M, Clark-Lewis I, Dahinden CA: Monocyte chemotactic protein MCP-2 activates human basophil and eosinophil leukocytes similar to MCP-3. J Immunol 154:4166, 1995
17. Dahinden CA, Geiser T, Brunner T, von Tscharner T, Caput D, Ferrara P, Minty A, Baggiolini M: Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med 179:751, 1994
18. Ponath PD, Qin S, Ringler DJ, Clark-Lewis, Wang I, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR: Cloning of the human eosinophil chemoattractant, eotaxin: Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 97:604, 1996
19. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD: Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 2:449, 1996
20. Elsner J, Höchstetter R, Kimmig D, Kapp A: Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol 26:1919, 1996
21. Schröder JM, Mrowietz U, Monta E, Christophers E: Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol 139:3474, 1987
22. Baggiolini M, Walz A, Kunkel SL: Neutrophil activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J Clin Invest 84:1045, 1989
23. Schröder JM, Persoon NL, Christophers E: Lipopolysaccharide stimulated human monocytes secrete apart from NAP-1/IL-8 a second neutrophil activating protein: NH2-terminal amino acid sequence identity with melanoma growth stimulatory activity (MGSA/gro). J Exp Med 171:1091, 1990
24. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M: Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med 171:1792, 1990
25. Meurer R, Riper GV, Feeney W, Cunningham P, Hora D, Springer MS, MacIntyre DE, Rosen H: Formation of eosinophilic and monocyte intradermal inflammatory sites in the dog by injection of human RANTES but not human monocytes chemoattractant protein 1, human macrophage inflammatory protein 1α, or human interleukin 8. J Exp Med 178:1913, 1993
26. Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T, Dash L, Page K, Solari R, Aldebert D, Capron M, Dahinden C, Bonnefoy JY: CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol 25:863, 1995
27. Ohkawara Y, Lim KG, Xing Z, Glibetic M, Nakano K, Dolovich J, Croitoru K, Weller PF, Jordana M: CD40 expression by human peripheral blood eosinophils. J Clin Invest 97:1761, 1996
28. Walsh GM, Mermod J, Hartnell A, Kay AB, Wardlaw AJ: Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is α4β1 (very late antigen-4) dependent. J Immunol 146:3419, 1991
29. Nakayama H, Sano H, Nishimura T, Yoshidi S, Iwamoto I: Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med 179:1145, 1994
30. Hadam MR: Cluster report: CDw52, in Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (eds): Leucocyte Typing IV. White Cell Differentiation Antigens. Oxford, UK, Oxford, 1989, p 670
31. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro A, Waldmann H: Removal of T cells from bone marrow for transplantation: A monoclonal anti-lymphocyte antibody that fixes complement. Blood 62:873, 1983
32. Hale G, Xia MQ, Tighe HP, Dyer MJS, Waldmann H: The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:118, 1990
33. Waldmann H, Or R, Hale G: Elimination of graft versus host disease by in vitro depletion of alloreactive lymphocytes using a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 2:483, 1984
34. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431, 1989
35. Xia MQ, Tone M, Packman L, Hale G, Waldmann H: Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 21:1677, 1991
36. Treumann A, Lifely RM, Schneider P, Ferguson MAJ: Primary structure of CD52. J Biol Chem 270:6088, 1995
37. Rowan WC, Hale G, Tite JP, Brett SJ: Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 7:69, 1995
38. Hale G, Waldmann H, Friend P, Calne R: Pilot study of CAMPATH-1: A rat monoclonal antibody which fixes complement, as an immunosuppressant in organ transplantation. Transplantation 42:308, 1986
39. Peters M, Gleich GJ, Dunnettte SL, Fukuda T: Ultrastructural study of eosinophils from patients with hypereosinophilic syndrome: A morphological basis of hypodense eosinophils. Blood 71:780, 1988
40. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ: CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 80:281, 1993
41. Rosenberg HF, Ackermann SJ, Tenen DG: Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med 170:163, 1989
42. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989, p 7.3
43. Nishikawa K, Morii T, Ako H, Hamada K, Saito S, Narita N: In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. J Allergy Clin Immunol 90:169, 1992
44. Hundt M, Schmidt RE: The glycosylphosphatidylinositollinked Fcγ receptor III represents the dominant receptor structure for the immune complex activation of neutrophils. Eur J Immunol 22:811, 1992
45. Elsner J, Dichmann S, Kapp A: Activation of the respiratory burst in human eosinophils by chemotaxins requires intracellular calcium fluxes. J Invest Dermatol 105:231, 1995
46. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ: Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 154:4749, 1995
47. Matteson EL, Yocum DE, St Clair EW, Achkar AA, Thakor MS, Jacobs MR, Hays AE, Heitman CK, Johnston JM: Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 38:1187, 1995
48. Isaacs JD, Mana VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, Clair EW, Schnitzer TJ, Johnston JM: Campath-1h in rheumatoid arthritis - An intravenous dose-ranging study. Br J Rheumatol 35:231, 1996
49. Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJS, Catovsky D, Mellstedt H: Humanized CD52 monoclonal antibody Campath-1h as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151, 1996